CA2948829A1 - Methods and compositions of dasotraline for treatment of adhd - Google Patents

Methods and compositions of dasotraline for treatment of adhd Download PDF

Info

Publication number
CA2948829A1
CA2948829A1 CA2948829A CA2948829A CA2948829A1 CA 2948829 A1 CA2948829 A1 CA 2948829A1 CA 2948829 A CA2948829 A CA 2948829A CA 2948829 A CA2948829 A CA 2948829A CA 2948829 A1 CA2948829 A1 CA 2948829A1
Authority
CA
Canada
Prior art keywords
dasotraline
dosage form
adhd
treatment
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948829A
Other languages
English (en)
French (fr)
Inventor
Antony D. Loebel
Kenneth S. Koblan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA2948829A1 publication Critical patent/CA2948829A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2948829A 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd Abandoned CA2948829A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
US61/992,588 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (1)

Publication Number Publication Date
CA2948829A1 true CA2948829A1 (en) 2015-11-19

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948829A Abandoned CA2948829A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Country Status (10)

Country Link
US (1) US20170266133A1 (enExample)
EP (1) EP3142999A4 (enExample)
JP (1) JP2017515858A (enExample)
KR (1) KR20170003677A (enExample)
CN (1) CN106660936A (enExample)
AU (1) AU2015259337A1 (enExample)
CA (1) CA2948829A1 (enExample)
IL (1) IL248846A0 (enExample)
MX (1) MX2016014780A (enExample)
WO (1) WO2015175514A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200405867A1 (en) * 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
PT1542961E (pt) * 2002-09-16 2013-11-05 Sunovion Pharmaceuticals Inc Trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1- naftalenamina para uso no tratamento de perturbações do sistema nervoso central
RU2016104396A (ru) * 2009-12-04 2018-11-23 Суновион Фармасьютикалз Инк. Лекарственные формы, соли и полиморфы транснорсертралина и их применения
EP2707000A4 (en) * 2011-05-13 2014-11-26 Dainippon Sumitomo Pharma Co TREATMENT AND CONTROL OF CNS DISORDERS

Also Published As

Publication number Publication date
IL248846A0 (en) 2017-01-31
AU2015259337A1 (en) 2016-12-08
JP2017515858A (ja) 2017-06-15
EP3142999A4 (en) 2017-12-27
WO2015175514A1 (en) 2015-11-19
MX2016014780A (es) 2017-07-25
EP3142999A1 (en) 2017-03-22
US20170266133A1 (en) 2017-09-21
KR20170003677A (ko) 2017-01-09
CN106660936A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
CA3073996C (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
US20130005764A1 (en) Quinine dosage forms and methods of use thereof
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
KR20120101456A (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
US20170266133A1 (en) Methods and compositions of dasotraline for treatment of adhd
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US10076503B2 (en) Dosage of dasotraline and method for treatment of ADHD
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
EP4362942A1 (en) Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Schmidt et al. P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia
Willis et al. P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123

FZDE Discontinued

Effective date: 20211123